Drummand M, Members of the ISPOR HTA Council Working Group on HTA in Pluralistic Healthcare Systems, Ronquest N. A case of multitasking: conducting and using HTA and HEOR in pluralistic healthcare systems. Value & outcomes spotlight. 2022 Jul;8(4):7-9.
Sauchelli S, Bradley J, Cox J, England C, Perry R. Weight maintenance interventions for people with type 2 diabetes mellitus: a systematic review protocol. Syst Rev. 2020 Sep 12;9(1):210. doi: 10.1186/s13643-020-01467-7
Davis AE, Brogan AJ, Goodwin B, Nocea G, Lozano V. Short-term cost and efficiency analysis of raltegravir versus atazanavir/ritonavir or darunavir/ritonavir for treatment-naive adults with HIV-1 infection in Spain. HIV Clin Trials. 2017 Nov;18(5-6):214-22. doi: 10.1080/15284336.2017.1402144
Demeyin (Nuabor) WA, Frost J, Ukoumunne OC, Briscoe S, Britten N. N of 1 trials and the optimal individualisation of drug treatments: a systematic review protocol. Syst Rev. 2017 Apr 24;6(1):90. doi: 10.1186/s13643-017-0479-6
Wolowacz SE. Task force recommendations on the collection of health-state utility data in clinical studies: an interview with Sorrel E. Wolowacz, PhD, Co-Chair, on good practices for Outcomes Research Task Force. Value & outcomes spotlight. 2016 Sep;2(5):22-3.
Alcubierre N, Navarrete-Muñoz EM, Rubinat E, Falguera M, Valls J, Traveset A, Vilanova MB, Marsal JR, Hernandez M, Granado-Casas M, Martinez-Gonzalez D, Jurjo C, Franch-Nadal J, Vioque J, Mauricio D. Association of low oleic intake acid with diabetic retinopathy in type 2 diabetic patients: a case-control study. Nutr Metab (Lond). 2016 Jun 4;13(40). doi: 10.1186/s12986-016-0099-5
Brogan AJ, Mrus J, Hill A, Sawyer AW, Smets E. Comparative cost-efficacy analysis of darunavir/ritonavir and other ritonavir-boosted protease inhibitors for first-line treatment of HIV-1 infection in the United States. HIV Clin Trials. 2010 May;11(3):133-44.